A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520788-42-00

Acronym

CRU3

Enrollment

Registered

2025-01-31

Start date

2019-09-26

Completion date

Unknown

Last updated

2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplastic Large Cells Lymphoma (ALCL) ALK+

Brief summary

ORR

Detailed description

PFS, OS, Toxicity, QoL, Mutational analysis

Interventions

DRUGLorviqua 25 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ORR	—

Secondary

Measure	Time frame
PFS, OS, Toxicity, QoL, Mutational analysis	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026